

Supplementary Material

Table 1S. Descriptive data of the study questionnaires

	No. patients (%)	Mean \pm SD (95% confidence interval)
Hoehn and Yahr staging (n = 173)		
Stage 1	16 (9.4)	
Stage 2	57 (33.3)	
Stage 3	51 (29.8)	
Stage 4	38 (22.2)	
Stage 5	9 (5.3)	
SCOPA Motor Scale (n = 173)		23.32 \pm 14.16 (21.19 – 25.44)
Examination (motor evaluation)		12.7 \pm 7.2 (11.7-13.8)
Activities of daily living		7.6 \pm 5.3 (7.0-8.4)
Dyskinesias		1.6 \pm 1.9 (1.3-1.8)
Motor fluctuations		2.0 \pm 1.8 (1.7-2.2)
Non-Motor Symptoms Scale (n = 173)		
Cardiovascular		1.0 \pm 1.9 (0.7-1.3)
Sleep/fatigue		9.2 \pm 8.3 (7.9-10.4)
Mood/apathy		9.5 \pm 14.4 (7.4-11.7)
Perceptual problems/hallucinations		1.4 \pm 3.6 (0.8-1.9)
Attention/memory		4.7 \pm 7.2 (3.6-5.8)
Gastrointestinal tract		4.5 \pm 5.6 (3.8-5.4)
Urinary function		7.9 \pm 8.3 (6.7-9.2)
Sexual function		3.9 \pm 6.0 (3.0-4.8)
Miscellaneous		6.9 \pm 6.9 (6.0-8.0)
Total score		49.0 \pm 40.2 (43.0-55.1)
Clinical Impression of Severity Index for PD (n = 169)		10.1 \pm 5.3 (9.3-11.*9)
Clinical Global Impression of Severity (n = 196)		
Normal, not at all ill	0	
Borderline	6 (3.5)	
Mildly ill	38 (22.9)	
Moderately ill	66 (38.4)	
Markedly ill	36 (20.9)	
Severely ill	25 (14.5)	
Among the most extremely ill patients	1 (0.6)	
Patient Global Impression of Severity (n = 172)		
Normal	5 (2.9)	
Very mild	8 (4.7)	
Mildly	39 (22.7)	
Moderately	75 (43.6)	
Severe	38 (22.1)	
Very severe	7 (4.1)	
Clinical judgement of PD stage (gold standard) (n = 173)		
Non-advanced	108 (62.4)	
Advanced	65 (37.6)	
CDEPA questionnaire (n = 173)		
Non-advanced	64 (37.0)	
Advanced	109 (63.0)	